Advanced search
Publication Cover
COPD: Journal of Chronic Obstructive Pulmonary Disease Volume 15, 2018 - Issue 5
Submit an article Journal homepage
410
Views
3
CrossRef citations to date
0
Altmetric
Original Articles

Comparative Effectiveness of Two Tiotropium Formulations: A Retrospective Cohort Study

Stefania Spila-AlegianiPharmacoepidemiology Unit, National Center for Drug Research and Evaluation, National Institute of Health (ISS), Rome, Italy; Correspondence[email protected]
,
Francesco TrottaItalian Medicines Agency (AIFA), Rome, Italy;
,
Roberto Da CasPharmacoepidemiology Unit, National Center for Drug Research and Evaluation, National Institute of Health (ISS), Rome, Italy;
,
Mariangela RossiUnit for Pharmaceutical Governance, General Directorate for Health, Perugia, Italy;
,
Mauro Venegoni Pharmacology Institute, University of Verona, Verona, Italy
&
Giuseppe TraversaPharmacoepidemiology Unit, National Center for Drug Research and Evaluation, National Institute of Health (ISS), Rome, Italy;
Pages 418-423 | Received 03 May 2018, Accepted 22 Nov 2018, Published online: 13 Jan 2019

References

  • Ram FS, Carvallho CR, White J. Clinical effectiveness of the Respimat inhaler device in managing chronic obstructive pulmonary disease: evidence when compared with other handheld inhaler devices. Int J Chron Obstruc Pulmon Dis. 2011;6:129–139. doi:10.2147/COPD.S8092.
  • Keating GM. Tiotropium Respimat® Soft Mist™ inhaler: a review of its use in chronic obstructive pulmonary disease. Drugs 2014;74(15):1801–1816. doi:10.1007/s40265-014-0307-4.
  • European Medicines Agency. Pharmacovigilance Risk Assessment Committee (PRAC). Minutes of the meeting- 7–10 January 2013 [accessed 2018 Apr 24]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Minutes/2013/02/WC500139251.pdf. .
  • Wise RA, Anzueto A, Cotton D, Dahl R, Devins T, Disse B, Dusser D, Joseph E, Kattenbeck S, Koenen-Bergmann M, et al. Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med. 2013;369:1491–1501. doi:10.1056/NEJMoa1303342.
  • Verhamme KMC, Afonso A, Romio S, Stricker BC, Brusselle GGO, Sturkenboom MCJM. Use of tiotropium Respimat Soft Mist Inhaler versus HandiHaler and mortality in patients with COPD. Eur Respir J. 2013;42:606–615. doi:10.1183/09031936.00005813.
  • Trotta F, Spila Alegiani S, Da Cas R, Rajevic M, Conti V, Venegoni M, Rossi M, Traversa G. Cardiovascular safety of tiotropium Respimat® vs HandiHaler in the routine clinical practice: a population-based cohort study. PLoS One. 2017;2(4): e0176276. doi:10.1371/journal.pone.0176276.
  • Schmiedl S, Fischer R, Ibanez L, Fortuny J, Thürmann P, Ballarin E, Ferrer P, Sabaté M, Rottenkolber D, Gerlach R, et al. Tiotropium Respimat vs. HandiHaler: real-life usage and TIOSPIR trial generalizability. Br J Clin Pharmacol. 2016;81:379–388. doi:10.1111/bcp.12808.
  • Trotta F, Da Cas R, Rajevic M, Rossi M, Traversa G. Risk factors influencing the prescription of tiotropium Respimat formulation: a population-based cohort study. BMJ Open. 2015;5: e006619. doi: 10.1136/bmjopen-2014-006619.
  • Scichilone N, Basile M, Battaglia S, Bellia V. What proportion of chronic obstructive pulmonary disease outpatients is eligible for inclusion in randomized clinical trials? Respiration. 2014;87:11–17. doi:10.1159/000355082.
  • Kruis AL, Ställberg B, Jones RCM, Tsiligianni IG, Lisspers K, van der Molen T, Kocks JWH, Chavannes NH. Primary care COPD patients compared with large pharmaceutically-sponsored COPD studies: an UNLOCK validation study. PLoS One. 2014;9: e90145. doi:10.1371/journal.pone.0090145.
  • Battaglia S, Scichilone N. Eligibility of real-life patients with COPD for inclusion in RCTs: a commentary. Resp Res. 2017;18:5. doi:10.1186/s12931-016-0494-5.
  • Wise R, Calverley PMA, Dahl R, Dusser D, Metzdorf N, Müller A, Fowler A, Anzueto A. Safety and efficacy of tiotropium Respimat versus HandiHaler in patients naive to treatment with inhaled anticholinergics: a post hoc analysis of the TIOSPIR trial. NPJ Prim Care Respir Med. 2015;25:15067. doi:10.1038/npjpcrm.2015.67.
  • Dahl R, Kaplan A. A systematic review of comparative studies of tiotropium Respimat® and tiotropium HandiHaler® in patients with chronic obstructive pulmonary disease: does inhaler choice matter? BMC Pulm Med. 2016;16:135. doi:10.1186/s12890-016-0291-4.
  • Singh S, Loke YK, Enright P, Furberg CD. Pro-arrhythmic and pro-ischaemic effects of inhaled anticholinergic medications. Thorax. 2013;68:114–116. doi:10.1136/thoraxjnl-2011-201275.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.